Stephanie van Hoppe

119 Brain accumulation of ponatinib and its active metabolite is limited by ABCB1 and ABCG2 44. Kalvass, J.C. and G.M. Pollack, Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm Res, 2007. 24(2): p. 265-76. 45. Bauer, M., et al., Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier. Clin Pharmacol Ther, 2016. 100(2): p. 131-41. 46. Sjostedt, N., et al., Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier. Pharm Res, 2014. 31(1): p. 1-19. 47. Badhan, R.K., M. Chenel, and J.I. Penny, Development of a physiologically-based pharmacokinetic model of the rat central nervous system. Pharmaceutics, 2014. 6(1): p. 97-136. 48. Whittle, S.B., et al., The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma. Invest New Drugs, 2016. 34(6): p. 685-692. 49. vanWaterschoot, R.A., et al., Midazolammetabolism in cytochrome P450 3A knockoutmice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol, 2008. 73(3): p. 1029-36. 50. Douxfils, J., et al., Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta- analysis. JAMA Oncol, 2016. 51. Malagola, M., C. Papayannidis, and M. Baccarani, Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives. Ann Hematol, 2016. 95(5): p. 681-93. 52. Yilmaz, M. and E. Jabbour, Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia. Semin Oncol, 2015. 42(6): p. 876-86. 53. Abid, M.B. and S. De Mel, Does ponatinib cross the blood-brain barrier? Br J Haematol, 2016.